A clinical trial of 5 mg psilocybin plus psychological support vs 25 mg psilocybin plus psychological support in adults with generalised anxiety disorder

This Phase IIb randomised, double-blind trial (n=96) will compare the efficacy and safety of 5 mg psilocybin plus psychological support versus 25 mg psilocybin plus psychological support in adults with severe generalised anxiety disorder (GAD). Participants will receive two doses, one month apart, and their symptoms will be assessed over a total study duration of 33 weeks.

The trial is being conducted at Clerkenwell Health in the UK and is funded by Psychennex Pty Ltd. It aims to determine whether higher doses of psilocybin (25mg) provide greater symptom reduction than lower doses (5mg) when combined with psychological support. Participants, aged 18-70, may or may not be taking selective serotonin reuptake inhibitors (SSRIs).

The primary outcome will be the change in anxiety symptoms measured using the Hamilton Anxiety Rating Scale (HAM-A) at week 8. Secondary outcomes include changes in depression, workplace productivity, healthcare use, and emotional breakthrough during the psychedelic experience. Safety assessments will track adverse effects such as nausea, increased heart rate, and psychological distress. All sessions will take place in a controlled setting with medical supervision.

Topic Anxiety Safety Depression
Compound Psilocybin
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Incannex Healthcare
Incannex Healthcare is a clinical-stage cannabinoid and psychedelic medicine developer.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.